As part of her efforts to advance breast cancer immunotherapy, Evanthia Roussos Torres, MD, PhD, member of the USC Norris Tumor Microenvironment Program, has been leading a study on the cancer drug known as entinostat. Now, her results indicate that in the treatment of breast cancer, entinostat induces changes to multiple myeloid cell types, reduced immunosuppression, increases antitumor immune responses and improves sensitivity to immune checkpoint inhibitors. She and her collaborators recently published their findings in Cancer Immunology Research.

“This work will aid in the development of novel strategies to improve response rates to immunotherapy of breast cancer,” said Torres, who is also an assistant professor of medicine at the Keck School of Medicine of USC.

To continue reading this story, click here.